Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + herombopag
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This investigational combination regimen consists of the alkylating agent cyclophosphamide and the thrombopoietin receptor agonist (TPO-RA) herombopag, administered in conjunction with standard immunosuppressive therapy (IST) comprising anti-lymphocyte globulin (ALG) and cyclosporine. Developed by the Institute of Hematology & Blood Diseases Hospital in China, the regimen is being evaluated as a first-line treatment for patients with severe aplastic anemia (SAA) who are not candidates for hematopoietic stem cell transplantation. Cyclophosphamide acts as a potent immunosuppressant by cross-linking DNA to deplete autoreactive T-cells, while herombopag stimulates the TPO receptor on hematopoietic stem cells and megakaryocytes to promote multilineage hematopoiesis and increase platelet production. The addition of moderate-dose cyclophosphamide to the standard ALG, cyclosporine, and herombopag backbone aims to improve early response rates and overall efficacy in treatment-naive SAA patients.
- Other names
- Cyclophosphamide added to standard immunosuppressive therapy with herombopag
02
Targets
TPOR (Thrombopoietin receptor)DNA
Beyond the preview
Go deeper on cyclophosphamide + herombopag.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + herombopag.